Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus irinotecan in KRAS wild-type third-line metastatic colorectal cancer
2007-004806-28Phase 2Completed
- Sponsor
- GERCOR
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and irinotecan in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by GERCOR. Primary endpoint: Objective response rate. Started Jan 2008; status: completed.
02
Drugs
panitumumabirinotecan
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004806-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004806-28.